Aldesleukin - ILTOO Pharma

Drug Profile

Aldesleukin - ILTOO Pharma

Alternative Names: ILT-101; Low dose il2 - ILTOO Pharma; Low dose rhIL2 - ILTOO Pharma; Low-dose interleukin-2 - ILTOO Pharma

Latest Information Update: 28 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Assistance Publique Hopitaux de Paris; INSERM; Universite Pierre et Marie Curie
  • Developer Assistance Publique Hopitaux de Paris; ILTOO Pharma
  • Class Antineoplastics; Interleukins; Recombinant proteins
  • Mechanism of Action Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Autoimmune disorders; Systemic lupus erythematosus; Type 1 diabetes mellitus
  • No development reported Multiple sclerosis

Most Recent Events

  • 28 May 2018 No recent reports of development identified for phase-I development in Multiple-sclerosis in France (Parenteral)
  • 31 May 2017 Servier signs a license option agreement with ILTOO Pharma to develop and commercialise aldesleukin for Systemic lupus erythematosus worldwide (except USA and Japan)
  • 01 Nov 2016 Phase-II clinical trials in Systemic lupus erythematosus in Austria, Bulgaria, France, Germany, Mauritius, Portugal, Romania, Spain (SC) (NCT02955615)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top